Expand ROIV Menu
ROIV MENU

ROIV Latest Press Releases

-- February 6, 2026 --

Priovant Announces Positive Phase 2 Results for Brepocitinib in Cutaneous Sarcoidosis (CS) Globe Newswire 7:00 AM
Roivant Announces Positive Phase 2 Results for Brepocitinib in Cutaneous Sarcoidosis (CS) and Reports Financial Results for the Third Quarter Ended December 31, 2025 Globe Newswire 7:00 AM
Pulmovant Announces Completion of Enrollment in the Phase 2 PHocus Study of Mosliciguat in Patients with Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD) Globe Newswire 7:00 AM

-- January 23, 2026 --

Immunovant to Report Financial Results for the Third Quarter Ended December 31, 2025, and Provide Business Update on Friday, February 6, 2026 Globe Newswire 5:25 PM
Roivant to Report Financial Results for the Third Quarter Ended December 31, 2025, and Provide Business Update on Friday, February 6, 2026 Globe Newswire 4:15 PM

-- December 11, 2025 --

Roivant Highlights Continued Pipeline Progress and Outlook for Company's Next Phase of Growth at 2025 Investor Day Globe Newswire 7:30 AM

-- November 10, 2025 --

Roivant Reports Financial Results for the Second Quarter Ended September 30, 2025, and Provides Business Update Globe Newswire 7:00 AM

-- October 27, 2025 --

Roivant to Report Financial Results for the Second Quarter Ended September 30, 2025, and Provide Business Update on Monday, November 10, 2025 Globe Newswire 4:10 PM
Immunovant to Report Financial Results for the Second Quarter Ended September 30, 2025, and Provide Business Update on Monday, November 10, 2025 Globe Newswire 4:10 PM

-- September 17, 2025 --

Roivant and Priovant Announce Positive Phase 3 VALOR Study Results for Brepocitinib in 52-Week Placebo-Controlled Trial in Dermatomyositis (DM) Globe Newswire 7:00 AM

-- September 11, 2025 --

Roivant Named on Fortune Media and Great Place To Work's 2025 Best Workplaces in BioPharma List Globe Newswire 4:30 PM
Market Data Delayed 15 Minutes